Towards a European production of stable isotopes for novel nuclear medicine therapies (SAMIRA/ERVI)

HORIZON-EURATOM supports EURATOM Innovation Actions to establish European production capacity for stable isotopes used in novel nuclear medicine therapies, with particular emphasis on Yb-176 for Lu-177. The topic has an indicative budget of €2,000,000 (around one grant) and uses lump-sum funding at 100% of eligible costs; the call opens 24 March 2026 and the submission deadline is 15 September 2026 at 17:00 Brussels time. Eligible applicants are legal entities established in EU Member States and Euratom-associated countries (currently including Ukraine and Switzerland), and proposals should focus on TRL 5–7 market-near activities delivered by consortia in line with the Euratom Work Programme.

Towards a European production of stable isotopes for novel nuclear medicine therapies (SAMIRA/ERVI)

Call snapshot

What it funds

Innovation actions to establish secure, scalable EU production of stable isotopes (notably Yb-176 and others used to produce therapeutic and theragnostic radioisotopes), focusing on close-to-market activities such as prototyping, piloting, demonstration and scaling-up; limited R&D permitted. Activities are expected around TRL 5 to 7 and must strengthen EU medical radioisotope supply chain resilience and align with SAMIRA and Europe’s Beating Cancer Plan.

Funding range:Indicative EU contribution per selected project is in the low millions (topic HORIZON-EURATOM shows an indicative contribution around €1–€3 millionper grant; final lump sum is fixed during grant preparation) ¹.

1. 1Who can apply: legal entities established in EU Member States and countries associated to the Euratom programme (see General Annexes for the up-to-date list); consortia are expected, Joint Research Centre may join and cover its own operational costs.
2. 2What to propose: consortium projects delivering industrial-scale or pilot production methods for stable isotopes (Yb-176, Gd and others), supply-chain integration, stakeholder engagement (industry, healthcare, policymakers) and routes to clinical/commercial uptake.

Eligibility, admissibility rules, lump-sum financial setup, evaluation criteria, page limits and country lists are described in the Euratom Work Programme General Annexes and the Funding & Tenders Portal topic page. Applicants must follow the application templates and submission process on the Portal and ensure compliance with ethics, security and national rules.

Primary information and submission are via the official topic page on the Funding & Tenders Portal Topic page.

Footnotes

1. 1Lump sum rules and method for setting final grant amounts are described in the Decision authorising lump sums under Horizon Europe and Euratom (see reference documents on the Funding & Tenders Portal or ec.europa.eu).

Towards a European production of stable isotopes for novel nuclear medicine therapies (SAMIRA/ERVI) — HORIZON-EURATOM-2026-01-05

Opportunity Overview

This is a forthcoming Horizon Europe Euratom Innovation Action under the Nuclear research and training programme. It targets the establishment of secure, sustainable EU-based production of key stable isotopes used to manufacture therapeutic and diagnostic radionuclides for nuclear medicine, with an emphasis on closer-to-market activities at TRL 5 to 7. The action aims to reduce the EU’s strategic dependence on imported stable isotopes, especially Yb-176 used to produce Lu-177 for radioligand therapies such as Lutetium-177-PSMA and Lutetium-177-Dotatate, and to expand production of other stable isotopes supporting emerging alpha and beta emitters (for example Gd for Tb isotopes). Proposals should cover prototyping, testing, demonstrating, piloting and scaling up production processes, with limited R&D. Strong interdisciplinary and cross-value-chain collaboration is expected, including industry, policy makers, healthcare professionals and the Joint Research Centre (JRC), whose facilities and expertise may be used. The call supports Europe’s Beating Cancer Plan and the Strategic Agenda for Medical Ionising Radiation Applications (SAMIRA).

Scope and Expected Outcomes

• Develop scalable, cost-effective EU production of stable isotopes critical for innovative nuclear medicine therapies, particularly Yb-176 for Lu-177 manufacturing.
• Strengthen resilience and security of the EU medical radioisotope supply chain by securing source materials, reducing dependence on third countries, and enhancing industrial-scale isotope sourcing and production.
• Leverage EU expertise in nuclear science, physics and engineering to develop and optimise isotope production processes, contributing to SAMIRA and Europe’s Beating Cancer Plan.
• Broaden the portfolio of therapeutic radioisotopes and theragnostic isotope pairs, including pathways for alpha and beta emitters (e.g., Gd for Tb isotopes), improving personalised options for diagnostics and therapy.
• Focus on market-near activities: prototyping, testing, demonstration, piloting and scaling-up of products or processes; limited R&D allowed.
• Indicative TRL: 5 to 7 (non-mandatory but expected given the market-near focus).
• Promote interdisciplinary collaboration and partnerships with industry, policy makers and healthcare professionals; engage stakeholders across the nuclear medicine value chain for feasibility, scalability and market integration.
• Encourage use of JRC services, facilities and expertise (the JRC may join consortia and will bear its own staff and infrastructure operational costs).

Categorisation and Structured Details

Eligible Applicant Types:Universities, research institutes, SMEs, large enterprises and industrial producers active in isotope enrichment and radiopharmaceutical supply chains, nuclear technology developers, hospitals and clinical networks involved in nuclear medicine, nonprofit and NGO actors relevant to health innovation ecosystems, public bodies including national laboratories and agencies, public-private partnerships, and the Joint Research Centre (JRC) as a consortium member. Any legal entity meeting Euratom eligibility may participate, with funding eligibility subject to country status as detailed under Geographic Eligibility.

Funding Type:Grant (lump sum) under a Euratom Innovation Action. Costs are funded via a pre-agreed lump sum per work package based on estimated eligible costs; payments are linked to proper implementation of work packages rather than actual costs incurred ¹.

Consortium Requirement:Consortium. As a standard Horizon Europe/Euratom Innovation Action, collaborative proposals are expected. The JRC may participate as a consortium member. Single-stage submission and evaluation.

Beneficiary Scope (Geographic Eligibility):Eligibility follows the Euratom Work Programme General Annexes. Applicants from EU Member States are eligible. As of publication, Ukraine and Switzerland are associated to the Euratom Programme and eligible for funding. Other participation rules follow Horizon Europe/Euratom: entities from additional countries may participate subject to the Work Programme eligibility conditions, with funding eligibility depending on association status and specific topic restrictions. Refer to the up-to-date List of Participating Countries (Horizon Europe/Euratom) for details EU Grants: List of participating countries (HE/Euratom) ¹.

Target Sector:Nuclear medicine, radiopharmaceuticals, oncology, healthcare, nuclear technologies, isotope production and enrichment, health supply chains, SAMIRA implementation, diagnostics and theragnostics. Cross-cutting with advanced manufacturing and industrial scaling of nuclear-related processes.

Mentioned Countries:Russia (as a current external supplier risk referenced in the topic context), Ukraine (associated to Euratom and eligible for funding), Switzerland (associated to Euratom and eligible for funding). Regionally, the EU is referenced throughout as the beneficiary area.

Project Stage:Development, validation, demonstration and scale-up. Indicative TRL 5 to 7, focused on prototyping, testing, demonstrating, piloting and scaling-up of stable isotope production methods and processes.

Funding Amount:Topic budget envelope indicates approximately €2,000,000 total EU contribution with an indicative number of grants of 1 for this topic, aligned with budget years 2026 and 2027 each listing €1,000,000. The call page indicates around €2,000,000 for this topic and a single-stage process.

Application Type:Open call, single-stage submission via the EU Funding & Tenders Portal submission system. Planned opening 24 March 2026; deadline 15 September 2026 at 17:00:00 Brussels time. Apply through the topic page HORIZON-EURATOM-2026-01-05.

Nature of Support:Money. Beneficiaries receive EU grant funding in lump sum form upon proper implementation of agreed work packages. Non-financial support includes recommended access to JRC facilities and expertise, if appropriate.

Application Stages:1 stage. Single-stage submission and evaluation model.

Success Rates:Not stated in the topic or call documentation provided. No historical or expected success rate figures are disclosed.

Co-funding Requirement:Lump sum grants follow Horizon Europe/Euratom reimbursement rules embedded in the lump sum calculation. The EU contribution is fixed during grant preparation as a reliable proxy of eligible costs; any share of costs not covered by the EU lump sum must be covered by the consortium. The reimbursement rate is factored into the lump sum during grant preparation; applicants must prepare a detailed estimated budget. Payments are made for completed work packages; up to 5-8% may be retained for the Mutual Insurance Mechanism as per Horizon Europe financial rules ¹.

Technical and Scientific Focus

• Secure EU-based production of Yb-176 as a precursor for Lu-177 manufacturing used in radioligand therapies such as Lutetium-177-PSMA for prostate cancer and Lutetium-177-Dotatate for neuroendocrine tumours.
• Develop production pipelines for other stable isotopes enabling alpha and beta emitters for targeted radiotherapy, for example Gadolinium for Terbium isotopes, broadening theragnostic isotope pairs.
• Design and optimisation of isotope enrichment, separation and purification processes suitable for industrial scale-up, including quality control, safety and regulatory compliance steps relevant to medical supply chains.
• Demonstration and pilot-scale operations validating throughput, yield, purity/isotopic enrichment targets, scalability, cost-effectiveness and lifecycle sustainability for EU deployment.
• Integration with downstream radionuclide and radiopharmaceutical manufacturing value chains to align production capacity with clinical and market needs.
• Risk reduction actions for supply-chain security, including diversification of sources, inventory strategies, and logistics for medical radioisotopes across the EU.

Conditions, Eligibility and Evaluation

• Admissibility: Layout and page limits per General Annexes to Euratom WP 2026-2027. For RIA and IA using lump sum, Part B page limit is 45 pages.
• Eligibility countries: Per General Annexes. As of publication, Ukraine and Switzerland are associated to Euratom and eligible for funding. See the dynamic list of participating countries for updates.
• Other eligible conditions: The JRC may participate as a member of the consortium selected for funding.
• Financial and operational capacity and exclusion: As per General Annexes (capacity checks and exclusion criteria apply).
• Evaluation and award: Submission and evaluation processes, award criteria, scoring and thresholds are per Euratom WP General Annexes and the Online Manual. Single-stage evaluation.
• Legal and financial set-up: Lump sum grants as authorised for Horizon Europe and Euratom; general provisions in Euratom WP General Annexes.

Budget Overview for the Call Family (extracts affecting this topic)

Submission and Key Dates

• Planned opening of submission system: 24 March 2026.
• Deadline: 15 September 2026 at 17:00:00 Brussels time.
• Submission: EU Funding & Tenders Portal via the topic page. Partner search and Q&A tools are available on the topic page.

Templates and How Applications Look

Applicants use the standard Horizon Europe Part A webforms and Part B narrative template for HE RIA/IA, adapted to lump sum. For this topic, Part B has a 45-page limit. The application package and model grant agreements are accessible from the call page and reference documents.

Part A (webforms):1. General Information: Acronym, title, duration, abstract, keywords, resubmission flag, declarations, ethics and security statements. 2. Participants: Organisation legal data (via PIC), contacts, roles, SME status, departments, links with other participants, key researchers, role in project, prior achievements and infrastructures, Gender Equality Plan status (where applicable). 3. Budget: Detailed lump sum budget table per participant and work package, including personnel, subcontracting, purchase costs, other cost categories, and indirect costs (25% flat rate accounted within lump sum calculation). 4. Ethics and Security: Ethics issues table and self-assessment; security issues table and self-assessment if applicable. 5. Other Questions: For two-stage calls (not applicable here), clinical study annex flag if relevant to the project.

Part B (upload, PDF, 45 pages for IA lump sum):Section 1 Excellence: Objectives and ambition; methodology including concepts, models and assumptions; interdisciplinarity; gender dimension in R&I content where relevant; open science practices and data management approach. Section 2 Impact: Project’s pathways to expected outcomes and wider impacts; barriers and requirements beyond the project; plan for dissemination, exploitation and communication including IP strategy and standardisation where relevant. Section 3 Implementation: Work plan overview; Gantt and PERT; detailed work packages with tasks, roles and quantified effort; deliverables; milestones; risks and mitigation; person-months by participant and WP; justification for subcontracting and major equipment where applicable; consortium capacity and access to critical infrastructures. Distinct items to include within first 6 months: Data Management Plan and Plan for dissemination and exploitation including communication activities. Applicants must follow the specific forms available in the Submission System.

Key reference templates and guidance:Application form templates (HE RIA IA), Detailed budget table (HE LS), Standard evaluation form (HE RIA IA), Horizon Europe and Lump Sum MGAs, EU Grants AGA — Annotated Model Grant Agreement, Online Manual. Lump sum decision and methodology guidance and the list of participating countries are available online EU Funding & Tenders Portal — Guidance and manuals ¹.

Evaluation, Award and Grant Setup

• Award criteria: Excellence, Impact, and Quality and efficiency of the implementation, per General Annexes for Euratom. Scoring and thresholds as defined in the General Annexes.
• Single-stage evaluation with external independent experts; lump sum budget robustness is checked against benchmarks, market and historical data; budget and work package shares may be adjusted during grant preparation.
• Legal and financial set-up: Lump sum per work package; payments upon proper implementation; no actual-cost reporting; technical reviews focus on results, research integrity, ethics, IPR, dissemination and exploitation.

Compliance, Ethics and Security

Proposals must comply with EU ethical standards and applicable legislation. Activities are civil in nature unless explicitly permitted otherwise in call conditions; dual-use items must follow export/import regulations. Standard Horizon Europe ethics self-assessment and security self-assessment (if applicable) are required within Part A, with additional annexes if necessary per the submission system. Radiation safety, environmental, and health and safety measures must be addressed where relevant to isotope production, handling and logistics.

What Strong Proposals Should Demonstrate

1. 1Clear, quantified production targets for priority stable isotopes (e.g., enrichment levels for Yb-176; throughput, yield and purity suitable for medical radionuclide production).
2. 2Validated, scalable process flows including enrichment, separation, purification, QA/QC, and integration with downstream Lu-177 and other radionuclide manufacturing.
3. 3Industrialisation pathway with pilot and demonstration activities at TRL 5–7, including regulatory and quality frameworks aligned to medical applications.
4. 4Robust supply-chain design for resilience and autonomy, with risk analysis against third-country dependence and logistics contingencies across the EU.
5. 5Engagement of the full value chain: isotope producers, radiopharmas, cyclotron/reactor operators where relevant, hospitals/clinicians, regulators/standardisation bodies, and policy stakeholders.
6. 6Data-driven cost and sustainability analysis showing competitiveness and long-term viability, including scale-up plans and investment leverage.
7. 7Comprehensive dissemination, exploitation and communication plan, including IPR strategy and routes to market and clinical uptake.

How to Get Support

• Topic page and submission: HORIZON-EURATOM-2026-01-05
• Online Manual and FAQs: Funding & Tenders Portal — Online Manual
• IT Helpdesk for submission issues: via Portal support pages
• Partner search tool available on the topic page to publish or respond to collaboration requests

Summary Explanation

This Euratom Innovation Action funds the development, demonstration and scale-up of EU-based production of critical stable isotopes for nuclear medicine, with a special focus on Yb-176 for Lu-177 manufacture and additional isotopes supporting emerging alpha and beta therapies. The opportunity responds to supply risks from third-country dependencies and aims to strengthen strategic autonomy, resilience and patient access to innovative radiopharmaceuticals across the EU. Projects should operate at TRL 5 to 7 and include prototyping, testing, demonstration, piloting and scaling-up, with limited R&D. Expected outputs include validated, scalable, and cost-effective isotope production processes, integration with clinical and industrial needs, and a widened portfolio of theragnostic options. Proposals are collaborative (consortium-based), single-stage, and funded via lump sum grants that emphasise technical performance and results delivery. Eligible applicants include research organisations, industry, hospitals and relevant public bodies from EU Member States and Euratom-associated countries (currently including Ukraine and Switzerland). Applications are submitted through the EU Funding & Tenders Portal, using standard Horizon Europe Part A and Part B forms with a 45-page limit for Part B. The action supports SAMIRA and Europe’s Beating Cancer Plan by securing critical inputs for radioligand therapies and by catalysing innovation and investment in Europe’s nuclear medicine value chain.

Footnotes

1. 1Lump sum use and methodology: Decision authorising the use of lump sum contributions under Horizon Europe and Euratom Lump sum decision. Country eligibility and association: EU Grants — List of participating countries (Horizon Europe/Euratom) Participating countries list. General guidance and manuals: Funding & Tenders Portal — Guidance and manuals.

Funding Opportunity Analysis: HORIZON-EURATOM-2026-01-05

Opportunity Overview

This is a European Union funding opportunity under the Euratom Research and Training Programme, specifically designed to support the development of European production capacity for stable isotopes used in novel nuclear medicine therapies. The call is part of the Strategic Agenda for Medical Ionising Radiation Applications (SAMIRA) and the European Radioisotope Valley Initiative (ERVI), both strategic EU initiatives aimed at securing Europe's supply of medical radioisotopes and reducing dependence on third-country suppliers, particularly Russia.

Call Details

Call Identifier:HORIZON-EURATOM

Call Title:Towards a European production of stable isotopes for novel nuclear medicine therapies (SAMIRA/ERVI)

Type of Action:EURATOM Innovation Actions (IA)

Programme:Euratom Research and Training Programme 2026-2027

Submission Model:Single-stage submission procedure

Timeline and Deadlines

Call Opening Date:24 March 2026

Submission Deadline:15 September 2026 at 17:00 Brussels time

Status:Forthcoming - not yet open for submissions

Funding Information

Total Budget Available:€2,000,000 (€1,000,000 for 2026 and €1,000,000 for 2027)

Indicative Number of Grants:Around 1 grant expected to be awarded

Estimated Grant Size:Approximately €2,000,000 per project

Funding Rate:100% of eligible costs (standard for Euratom Innovation Actions)

Cost Model:Lump sum contributions based on estimated eligible costs

Scope and Objectives

The call aims to support the development of European production capacity for stable isotopes essential for manufacturing radionuclides used in novel nuclear medicine therapies. The primary focus is on Ytterbium-176 (Yb-176), which is critical for Lutetium-177 (Lu-177) manufacturing and used in radiopharmaceuticals such as Lutetium-177-PSMA for prostate cancer treatment and Lutetium-177 Dotatate for neuroendocrine tumour therapies. The call also considers production of other stable radioisotopes such as Gadolinium (Gd) for Terbium (Tb) isotope manufacturing.

Key strategic objectives include reducing EU dependence on Russian suppliers for critical stable isotopes, strengthening the resilience and security of the EU medical radioisotope supply chain, developing innovative and scalable production methods, and supporting Europe's Beating Cancer Plan through enhanced access to advanced nuclear medicine therapies.

Expected Outcomes

• Support for development of EU production of stable isotopes essential for manufacturing radionuclides used in novel nuclear medicine therapies
• Strengthening of resilience and security of the EU medical radioisotope supply chain by securing access to source materials
• Reduction of dependence on third countries and enhancement of industrial-scale production capacity
• Leveraging of knowledge and expertise of nuclear scientists, physicists and engineers to develop and optimise EU-based production processes
• Contribution to Europe's Beating Cancer Plan and implementation of the Strategic Agenda for Medical Ionising Radiation Applications (SAMIRA)

Eligibility Criteria

Eligible Participants

Legal entities established in EU Member States and Associated Countries are eligible for funding. As of the call publication date, Ukraine and Switzerland are the only countries associated to the Euratom Programme and therefore eligible for funding. The Joint Research Centre (JRC) may participate as a member of the consortium selected for funding, with the JRC bearing operational costs for its own staff and research infrastructure.

Participants from non-associated third countries may participate but generally without EU funding, unless their participation is deemed essential for project implementation based on outstanding competence, access to particular research infrastructures, geographical environments, or specific data. Entities subject to EU restrictive measures are not eligible to participate in any capacity.

Consortium Requirements

While specific consortium size requirements are not explicitly stated in the call documentation, proposals must demonstrate that the consortium brings together the necessary expertise and capacity to achieve project objectives. Interdisciplinary collaboration is essential, and the initiative should foster partnerships with industry, policymakers and healthcare professionals to ensure a comprehensive approach aligning production capacity with clinical and commercial needs.

Admissibility Conditions

• Proposal page limit: 45 pages maximum for Part B (technical description) using lump sum funding
• Proposals must follow the standard application form template provided in the submission system
• A plan for dissemination and exploitation including communication activities must be provided
• Explicit consent of all applicants on their participation and proposal content is required
• Confirmation that project activities have not started before proposal submission (unless explicitly authorised)
• Declaration of compliance with eligibility criteria and exclusion grounds under EU Financial Regulation

Technical and Implementation Requirements

Technology Readiness Level (TRL)

Activities are expected to focus on Technology Readiness Levels 5 to 7, which correspond to closer-to-the-market activities including prototyping, testing, demonstrating, piloting and scaling up of new or improved products or processes. Proposals may include limited research and development activities. The indicative TRL range is not mandatory and may vary depending on the innovative potential of the field.

Work Plan and Duration

Proposals must include a detailed work plan structured into work packages with clear objectives, deliverables, and milestones. The work plan should demonstrate how activities are sequenced and interdependent. A distinct work package on project management is recommended, with due visibility given to data management, dissemination and exploitation, and communication activities. Proposals must include a data management plan as a deliverable within the first 6 months of the project.

JRC Involvement

The Commission recommends that consortia use the Joint Research Centre's services where appropriate. The JRC may participate in the preparation and submission of the proposal and would bear operational costs for its own staff and research infrastructure operational costs. The JRC's facilities and expertise are listed in General Annex H of the Euratom Work Programme 2026-2027.

Evaluation Criteria

Proposals will be evaluated against three main criteria: Excellence, Impact, and Quality and Efficiency of Implementation. Each criterion carries specific assessment requirements.

Excellence

• Clarity and pertinence of project objectives and extent to which proposed work is ambitious and goes beyond state of the art
• Soundness of proposed methodology including underlying concepts, models, assumptions and interdisciplinary approaches
• Quality of open science practices including sharing and management of research outputs
• Integration of gender dimension in research and innovation content where relevant
• Appropriate consideration of social sciences and humanities where applicable

Impact

• Credibility of pathways to achieve expected outcomes and impacts specified in the work programme
• Suitability and quality of measures to maximise expected outcomes and impacts
• Quality of dissemination and exploitation plan including communication activities
• Clarity on target groups and how they will benefit from project results
• Identification of barriers and proposed mitigation measures

Quality and Efficiency of Implementation

• Quality and effectiveness of the work plan and assessment of risks
• Appropriateness of effort assigned to work packages and resources overall
• Capacity and role of each participant
• Extent to which consortium brings together necessary expertise
• Access to critical infrastructure needed for project activities
• Justification for participation of entities from non-eligible countries if applicable

Eligible Costs and Budget Structure

Eligible costs under lump sum funding include personnel costs, subcontracting costs, purchase costs (travel and subsistence, equipment, other goods and services), and other cost categories such as financial support to third parties and internally invoiced goods and services. Indirect costs are calculated at a flat rate of 25% of eligible direct costs.

Applicants must propose the lump sum amount based on estimated direct and indirect project costs and provide a detailed breakdown showing the share per work package and per beneficiary. The proposal must show that costs are eligible under Horizon Europe rules and exclude ineligible costs. Purchases and subcontracting must be done taking into account best value for money and must be free of conflict of interest.

Strategic Context and Policy Alignment

This call is part of the EU's comprehensive response to secure medical radioisotope supply and support cancer treatment innovation. The SAMIRA Action Plan, adopted in February 2021, defines three priority areas: securing the supply of medical radioisotopes, improving radiation quality and safety in medicine, and facilitating innovation in medical ionising radiation applications. The European Radioisotope Valley Initiative (ERVI), launched as a flagship initiative, aims to maintain Europe's global leadership in medical radioisotope supply and accelerate development of new radioisotopes and production methods ¹.

The call directly supports Europe's Beating Cancer Plan and addresses a critical strategic vulnerability: the EU's reliance on Russia for Yb-176 and other stable isotopes essential for innovative cancer therapies. Over €10 millionEuropean patients annually benefit from nuclear medicine procedures, making secure radioisotope supply essential for maintaining access to vital medical treatments and supporting development of new cancer treatments.

Key Considerations for Applicants

• Focus on closer-to-the-market activities with clear pathways to industrial-scale production and commercialisation
• Demonstrate how the project will reduce EU dependence on external suppliers and enhance strategic autonomy in isotope production
• Include partnerships with industry, healthcare professionals and policymakers to ensure market integration and clinical relevance
• Provide detailed cost estimates based on actual accounting practices and justify all resource requests
• Address open science practices and data management from project outset
• Include comprehensive dissemination and exploitation strategy with specific target groups and communication channels
• Identify and mitigate critical risks to project implementation
• Consider gender dimension in research content where relevant
• Ensure consortium has complementary expertise spanning nuclear science, engineering, production technology and healthcare applications

Grant Agreement and Financial Management

Successful proposals will be subject to a Model Grant Agreement (MGA) for Euratom Action Grants with budget-based lump sum contributions. Payments do not depend on costs actually incurred but rather on proper implementation of corresponding work packages in accordance with the grant agreement. Pre-financing will follow standard Horizon Europe rules, with 5-8% of total lump sum retained as contribution to the Mutual Insurance Mechanism. There are no financial checks or audits on actual costs; instead, controls focus on technical implementation, ethics, research integrity, dissemination and exploitation of results, and management of intellectual property.

Submission and Support

Proposals must be submitted through the EU Funding and Tenders Portal submission system. The standard application form (Part A) is generated by the IT system based on information entered by participants. Part B (technical description) must be uploaded as a PDF document following templates provided in the submission system. Applicants should consult the Online Manual on the Funding and Tenders Portal for step-by-step guidance through the submission process. IT helpdesk support is available for technical questions regarding the submission system.

Applicants are advised to review the Euratom Work Programme 2026-2027, General Annexes, and all referenced guidance documents before preparing proposals. The Commission provides detailed guidance on ethics and security issues, open science practices, data management, and gender dimension integration in research and innovation.

Footnotes

1. 1The European Radioisotope Valley Initiative (ERVI) was developed following extensive stakeholder consultation in 2022 and a feasibility study completed in March 2026. ERVI aims to strengthen resilience of the European supply chain for medical radioisotopes and secure equitable access of European patients to innovative cancer treatments through coordinated investments, research and development, and monitoring and forecasting mechanisms.